BFRA - Biofrontera stock jumps 7% on Ameluz supply deal in Poland

Biofrontera (BFRA) pops 6.6% premarket after its wholly owned subsidiary signed an exclusive license and supply agreement with Germany-based Medac Gesellschaft für klinische Spezialpräparate mbH for the marketing of both Ameluz and BF-RhodoLED in Poland. Under the terms of the agreement, Medac will make an immediate one-time upfront payment of €50,000 to the Company, plus an additional one-time payment of €150,000 following receipt of the drug's reimbursement eligibility from the Polish health insurance providers.Also, Medac receives exclusive distribution rights for Poland. Once reimbursement eligibility has been granted, Biofrontera will supply Ameluz to Medac at a fixed transfer price based on the expected net revenues.The agreement has a term of 5 years commencing with the start of sales in Poland. As with all of the company's other licensing agreements, Biofrontera will be responsible for regulatory affairs as well as manufacturing and quality control, while Medac will handle all aspects of commercialization and local regulatory and reimbursement in

For further details see:

Biofrontera stock jumps 7% on Ameluz supply deal in Poland